A new study indicates semaglutide, the active ingredient in Ozempic, may reduce Alzheimer's risk by 40-70% in type 2 diabetes patients, offering hope for prevention.
The researchers analyzed electronic health records of over 1 million U.S. patients aged 60 and older, concluding that those treated with semaglutide showed a significantly lower risk of Alzheimer's, particularly compared to traditional diabetes medications.
This study highlights that semaglutide not only treats type 2 diabetes but also correlates with a dramatically reduced risk of developing Alzheimer's disease, underscoring its potential beyond weight loss.
While the exact mechanisms by which semaglutide may lower Alzheimer's risk remain unclear, these findings provide a promising perspective on utilizing existing diabetes medications for neurological health.
Collection
[
|
...
]